alteplase should be justified.
Thanks for reviewer"s insightful suggestions. As reviewer speculates, tenecteplase is not approved in China. We have added the related information in the Introduction section as following: "tPA has been approved by China FDA, but Tenecteplase has not yet entered the Chinese market." 2. The authors indicate IRA patency by non invasive means as a secondary endpoint, however tit is not clear why the specified indirect indicators of IRA patency are based on; specific references to these indicators should be included
The gold standard for the diagnosis of failed reperfusion is a combination of coronary angiography and myocardial contrast imaging. However, some reliable non-invasive marker has been incorporated into clinical routine use for convenience, including resolution of chest pain, ST segment resolution, and biochemical diagnosis of failed thrombolysis. The related references have been cited in our revised manuscript: Davies CH, Ormerod OJ. Lancet. 1998; 351(9110) :1191-6. Chinese Journal of Cardiology Editorial Board. Reference scheme for treatment of fibrinolytic therapy for acute myocardial infarction. Chinese Journal of Cardiology 1996; 24(5): 3. The authors should specify if the composite primary endpoint will be hierarchical.
Our primary endpoint is MACCEs without hierarchical structure. But we would like to hear your advices.
4. The authors should discuss whether Kaplan Meier curves will be used for assessment of MACCE at 30 days, in addition to MV regression. Further, the authors should clearly indicate whether the primary endpoint analysis will be based on the ITT vs per protocol population primarily.
Kaplan Meier curves will be used to depict the occurrence of MACEE within 30 days of fibrinolytic therapy, and it has been shown in our statistical analysis methods as following: "Survival curves of MACCEs within 30 days of fibrinolytic therapy were estimated by Kaplan-Meier method and compared by log-rank test." We have described the analysis population definition in statistical analysis methods as following: "Both intention-to-treat (ITT) and per-protocol analyses will be done for the primary analyses as is recommended for non-inferiority studies, but principally with reference to per-protocol analysis."
Minor comments 1. MACCE should be clearly defined in the abstract.
We have supplemented the definition of MACCE in abstract as following: "MACCEs were defined as comprising all causes of death, non-fatal reinfarction, non-fatal stroke (both ischemic and hemorrhagic), percutaneous coronary interventions (PCI) due to thrombolysis failure and PCI due to reocclusion." 2. There is no indication of an institutional approval process in each participating hospital, please clarify further. Also, please indicate whether investigators and the study Sponsor will have (or not) access to the data until the study completion.
We have clarified this question in Ethical approval section as following:
"The protocol and informed consent form have been reviewed and approved by all participating hospitals" Privilege of data access is indicated the in the Competing interests section as following: "Principal investigator has full access to the final trial data set, but the sponsor doesn"t have access to the data." 3. Please move the discussion regarding the function of the DSMB to a more relevant section (it is currently under statistical considerations, it should be ideally moved either in the endpoint section or under a separate paragraph)
As suggested, the description on the function of the DSMB has been setup as a separate paragraph named as "Safety data monitoring" following Study endpoints section.
4. Several unclear sentences should be rewritten; for example, on page 14 (par 1), it is stated that "... the efficacy and safety of Recomlyse can be assumed to be optional..."
Thanks for reviewer"s kind reminding. It has been revised as following: "the efficacy and safety of rhTNK-tPA (Recomlyse®) can be assumed to be ideal" 
Please leave your comments for the authors below A protocol is presented for a randomized controlled trial of rhTNK-tPA vs rt-PA in patients with STEMI in China at 150 sites who are unable to undergo PCI within 90 minutes. The study is planned as a non-inferiority analysis with primary endpoint of MACCEs within 30 days of fibrinolytic therapy. However, the objective appears more in line with improving "timely reperfusion therapy and hence treatment outcomes". Therefore if the trial is positive, on what basis is it expected that tenectoplase would be chosen over alteplase?
Thanks reviewer for his constructive suggestions on the current protocol. Indeed, timely reperfusion is the key to reduce mortality and morbidity of STEMI patients. However, it is not the basis for conducting the current study. rt-PA has relatively quick plasma clearance and short half-life, therefore, high dose intravenous infusion is required to maintain effective drug concentration resulting in inconvenience in first-aid. Whereas rhTNK-tPA has significant advantages compared with rt-PA, including ease administration as a bolus, longer half-life and better fibrin specificity. It is hard to prove the superiority of therapeutic effect of rhTNK-tPA compared with rt-PA, especially in clinical trials in which rigorous management was conducted to keep high quality of study. However, for the treatment of acute disease such as STEMI, convenience is one of the important factors to be considered in first-aid. Inconvenience may result in indirect therapeutic effect in common clinical practices. Therefore, we think convenience in first-aid is one important reason for considering rhTNKtPA in clinical practices.
Given the results of the ASSENT-2 trial, what is the rationale for pursuing the current clinical trial?
ASSENT-2 trial, in which 16949 participants from more than 1,000 hospitals in 29 countries were randomized, showed that single-bolus tenecteplase and front-loaded altiplase had equivalent effect on 30-day mortality. Tenecteplase (TNKaseTM, Genentech Inc.), has been approved by the US Food and Drug Administration (FDA) in 2000, but Tenecteplase has not yet entered the Chinese market. The corresponding information has been shown in our background section. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA, Recomlyse®, Guangzhou Recomgen Biotech Co., Ltd.) with the same amino acid sequence with tenecteplase, has been developed by Guangzhou Recomgen Biotech Co.,Ltd., China. The difference in therapeutic effects between rhTNK-tPA and Tenecteplase has not been studied in Chinese population although similar study was conducted in other countries. Moreover, it is the requirement of China FDA to further validate its" efficacy and safety in clinical practices. In ASSENT-2 trial, the primary endpoint was allcause mortality at 30 days, whereas in the current study, the primary endpoint is the occurrence of MACCEs within 30 days of fibrinolytic therapy, including all causes of death, non-fatal reinfarction, non-fatal stroke (both ischemic and hemorrhagic), PCI due to thrombolysis failure and PCI due to reocclusion. The primary endpoint in the current study can more comprehensively reflect the efficacy of fibrinolytic therapy. Therefore, it is necessary to conduct the current study to validate efficacy and safety of rhTNK-tPA among Chinese population.
The protocol indicates that patients may be given rescue PCI as soon as possible if fibrinolysis fails. What percentage of patients are expected to undergo rescue PCI and how will use of rescue PCI be accounted for in the outcomes analysis?
It is estimated that 12% participants would undergo rescue PCI due to fibrinolysis failure. Rescue PCI has been included in our primary endpoint to account its" impact. The primary study endpoint is the occurrence of MACCEs within 30 days of fibrinolytic therapy, including all causes of death, non-fatal reinfarction, non-fatal stroke (both ischemic and hemorrhagic), PCI due to thrombolysis failure and PCI due to reocclusion.
Of the secondary study endpoints, items (c)-(f) appear to be a repetition of the primary study endpoints. How are these different?
The primary endpoint is a composite endpoint in the current study, including all causes of death, nonfatal reinfarction, non-fatal stroke (both ischemic and hemorrhagic), PCI due to thrombolysis failure and PCI due to reocclusion. In addition to the composite endpoint, we also hope determining the efficacy and safety on each of these single component of the primary endpoint. Moreover, it is a common practice in clinical research.
The monitoring protocol suggests that the DSMB will review major bleeding events and safety data monthly. Will there be a planned interim analysis and at what point? Are safety thresholds determined for stopping the trial early?
Thanks reviewer for his important suggestion on this topic. As this trial is a non-inferiority study, an interim analysis is not considered and statistical early stopping criteria will not be applied. The DSMB is not going to meet on monthly intervals. The safety data analyses should be done after 10%, 25% and 50% patients completing the study procedure respectively, and DSMB may recommend stopping the study anytime based on safety concerns. We have added related information in "Safety data monitoring" section.
